International Comparison of Medicines Usage: Quantitative Analysis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia
ANTICANCER RESEARCH 27: 1547-1552 (2007) Fludarabine, Treosulfan and Etoposide Sensitivity and the Outcome of Hematopoietic Stem Cell Transplantation in Childhood Acute Myeloid Leukemia JAN STYCZYNSKI1, JACEK TOPORSKI2, MARIUSZ WYSOCKI1, ROBERT DEBSKI1, ALICJA CHYBICKA2, DARIUSZ BORUCZKOWSKI3, JACEK WACHOWIAK3, BEATA WOJCIK4, JERZY KOWALCZYK4, LIDIA GIL5, WALENTYNA BALWIERZ6, MICHAL MATYSIAK7, MARYNA KRAWCZUK-RYBAK8, ANNA BALCERSKA9 and DANUTA SONTA-JAKIMCZYK10 1Department of Pediatric Hematology and Oncology, Medical College, Nicolaus Copernicus University, ul. Curie-Sklodowskiej 9, 85-094 Bydgoszcz; 2Department of Pediatric Transplantology, Hematology and Oncology, Medical University, ul. Bujwida 44, 50-345 Wroclaw; 3Department of Pediatric Transplantology, Hematology and Oncology, Medical University, ul. Szpitalna 27/33, 60-572 Poznan; 4Department of Pediatric Hematology and Oncology, Medical University, ul. Chodzki 2, 20-093 Lublin; 5Department of Hematology, Medical University, ul. Szamarzewskiego 84, 60-569 Poznan; 6Department of Pediatric Oncology/Hematology, Medical College, Jagiellonian University, ul. Wielicka 265, 30-663 Krakow; 7Department of Pediatric Hematology and Oncology, Medical University, ul. Marszalkowska 24, 00-576 Warsaw; 8Department of Pediatric Hematology and Oncology, Medical University, ul. Waszyngtona 17, 15-274 Bialystok; 9Department of Pediatric Hematology, Oncology and Endocrinology, Medical University, ul. Debinki 7, 80-210 Gdansk; 10Department of Pediatric Hematology and Oncology, Medical University, ul. -
LGM-Pharma-Regulatory-1527671011
Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide -
Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs. -
Protocol Supplementary
Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf. -
Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds
Syracuse University SURFACE Syracuse University Honors Program Capstone Syracuse University Honors Program Capstone Projects Projects Spring 5-1-2012 Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds Seungmo Suh Follow this and additional works at: https://surface.syr.edu/honors_capstone Part of the Biochemistry Commons Recommended Citation Suh, Seungmo, "Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds" (2012). Syracuse University Honors Program Capstone Projects. 151. https://surface.syr.edu/honors_capstone/151 This Honors Capstone Project is brought to you for free and open access by the Syracuse University Honors Program Capstone Projects at SURFACE. It has been accepted for inclusion in Syracuse University Honors Program Capstone Projects by an authorized administrator of SURFACE. For more information, please contact [email protected]. 1 Chapter 1: Background 1.1 Introduction The chemistry of transition metal phosphonates has enormous potential and diverse applications such as gas separation, gas storage or catalyst systems which have been explored in detail.1-6 In contrast, analogous chemistry with the s- block elements has received only a little attention. Calcium was the priority element in our study due to its bioactive properties. Previous studies proved that phosphonates can possibly be used as bone repair materials. 1 The possible applications are only possible with structures with pores or channels for other molecules to enter. Thus, the control of the shape and -
(GE) Review of TA160, 161 and 204; Technologies for The
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA160, 161 and 204; Technologies for the primary and secondary prevention of osteoporotic fractures1 TA160 and TA161 give guidance on alendronate, risedronate, etidronate, strontium ranelate, raloxifene and teriparatide, and were re-issued after the Judicial Review in January 2011. TA204 gives guidance on denosumab and was issued in October 2010. TA160 and TA161 were to be considered for review after the short clinical guideline on risk assessment has been published. TA204 was to be considered for review at the same time that TA160 and TA161 are considered for review. In August 2012 the clinical guideline on assessing the risk of fragility fractures in people with osteoporosis was published (CG146). In July 2012 Guidance Executive agreed to reschedule the review proposal for the above technology appraisals so that we can explore how treatment intervention thresholds from the technology appraisals can be aligned to the assessment of absolute fracture risk recommended in CG146, and to carry out a feasibility study through NICE’s Decision Support Unit. 1 Review of TA160; Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women, TA161; Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women, and TA204; Denosumab for the prevention of osteoporotic -
Active Pharmaceutical Ingredients
Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). -
)&F1y3x PHARMACEUTICAL APPENDIX to THE
)&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE -
Tiludronate 1105 Osteoporosis
Strontium Ranelate/Tiludronate 1105 Osteoporosis. Strontium ranelate, given orally with calcium temic hypersensitivity reactions should be borne in mind. Hyper- Data on combination therapy are limited, but some studies sug- and vitamin D supplements, has been found to reduce the risk of calcaemia may develop with teriparatide or the acetate and it is gest that teriparatide with HRT is more effective than HRT vertebral1 and non-vertebral2 fractures in postmenopausal wom- therefore contra-indicated in patients with pre-existing hypercal- alone.9 The effect of teriparatide with the antiresorptive bisphos- en with osteoporosis. A pooled analysis of data from these 2 caemia. phonates has yet to be determined.2,6,9,10 Although there is some studies concluded that strontium ranelate reduced both vertebral suggestion that teriparatide still increases bone formation after 3 Teriparatide is contra-indicated in patients with severe renal im- 9 and non-vertebral fractures in patients aged 80 years or older. pairment and should be used with caution with those with mod- treatment with alendronate, a study in men found that, when Protection against fractures was detected within 12 months, and erate impairment. given together, alendronate impaired the anabolic effects of teri- sustained throughout 3 years of treatment. Hip fractures were paratide.11 For this reason, some consider that teriparatide be also reduced over 3 years, but this did not reach statistical signif- There have been reports of osteosarcoma in rats given teripara- started immediately after stopping bisphosphonates.10 It has been icance; the authors concluded that the analysis may not have tide and patients who may be at increased risk, including those suggested that the degree of suppression of bone turnover before been sufficiently powered in this respect. -
Chapter 1.Pdf
CHAPTER 1 INTRODUCTION AND OUTLINE OF THIS THESIS INTRODUCTION Inflammatory bowel diseases (IBD), comprising Crohn’s disease, ulcerative colitis and IBD- 1 unclassified, are chronic recurrent inflammatory disorders of the (large) intestine with a heterogeneous, but often disabling disease presentation. The prevalence of IBD is increasing worldwide and medical therapies are introduced earlier to improve health-related quality of life and postpone surgical interventions1,2. This has led to the more extensive use of immunosuppressive therapies including biologicals and thiopurines. While the use of tioguanine was soon abandoned due to toxicity concerns3, over the years efficacy data on the use of azathioprine and mercaptopurine for the treatment of IBD has grown4,5. However, due to side effects and ineffectiveness, related to unprofitable metabolism, thiopurine therapy often fails; up to 50% of patients discontinues treatment within 2 years6. Increasing the knowledge on thiopurine metabolism may provide opportunities to further explore the therapeutic usefulness of thiopurines, which both from a patient’s perspective and a pharmacoeconomic perspective is essential. THIOPURINES In the 1950’s Gertrude Elion (1918-1999) worked as an assistant to George Hitchings (1905- 1998), both employees of Burroughs-Wellcome, focussing on the advent of drugs that inhibited cell growth without doing harm to the host cells. They discovered that purine bases are essential components of nucleic acids and vital for cell growth7. Subsequently, they designed the purine antagonists diaminopurine and tioguanine that blocked the synthesis of original nucleic acids and inhibited cell growth8. For the first time a successful treatment of leukaemia became available. Some years later Elion and colleagues also developed mercaptopurine, azathioprine, allopurinol, trimethoprim and acyclovir. -
Date Database Search Strategy Filters Results Results After Duplicates
Date Database Search Strategy Filters Results Results after Duplicates Removed 12/12/2018 PubMed (("Patient Participation"[Mesh] OR "Patient Participation" OR “Patient Filters: 120 108 Involvement” OR “Patient Empowerment” OR “Patient Participation Rates” English OR “Patient Participation Rate” OR “Patient Activation” OR “Patient Engagement” OR "Refusal to Participate"[Mesh] OR "Refusal to Participate" OR "Self Care"[Mesh] OR "Self Care" OR "Self-Care" OR “Well-being” OR Wellbeing OR “well being” OR "Walking"[Mesh] OR Walking OR Walk OR Walked OR Ambulation OR "Gait"[Mesh] OR Gait OR Gaits OR "Mobility Limitation"[Mesh] OR "Mobility Limitation" OR Mobility OR “Mobility Limitations” OR “Ambulation Difficulty” OR “Ambulation Difficulties” OR “Difficulty Ambulation” OR “Ambulatory Difficulty” OR “Ambulatory Difficulties” OR “Difficulty Walking” OR "Dependent Ambulation"[Mesh] OR "Dependent Ambulation" OR “functional status” OR “functional state” OR "Community Participation"[Mesh] OR "Community Participation" OR “Community Involvement” OR “Community Involvements” OR “Consumer Participation” OR “Consumer Involvement” OR “Public Participation” OR “Community Action” OR “Community Actions” OR "Social Participation"[Mesh] OR "Social Participation" OR "Activities of Daily Living"[Mesh] OR "Activities of Daily Living" OR ADL OR “Daily Living Activities” OR “Daily Living Activity” OR “Chronic Limitation of Activity” OR "Quality of Life"[Mesh] OR "Quality of Life" OR “Life Quality” OR “Health- Related Quality Of Life” OR “Health Related Quality Of -
Combination Effects of Radiotherapy / Drug Treatments for Cancer Recommendation by the German Commission on Radiological Protection with Scientific Background
Strahlenschutzkommission Geschäftsstelle der Strahlenschutzkommission Postfach 12 06 29 D-53048 Bonn http://www.ssk.de + Combination Effects of Radiotherapy / Drug Treatments for Cancer Recommendation by the German Commission on Radiological Protection with scientific Background Adopted at the 264th session of the SSK on 21 October 2013 Combination Effects of Radiotherapy / Drug Treatments for Cancer 2 The German original of this English translation was published in 2013 by the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety under the title: Kombinationswirkungen Strahlentherapie/medikamentöse Tumortherapie Empfehlung der Strahlenschutzkommission mit wissenschaftlicher Begründung This translation is for informational purposes only, and is not a substitute for the official statement. The original version of the statement, published on www.ssk.de, is the only definitive and official version. Combination Effects of Radiotherapy / Drug Treatments for Cancer 3 Contents Preface ....................................................................................................................... 8 Recommendation ...................................................................................................... 9 Scientific background of the recommendation .................................................... 11 1 Introduction ..................................................................................................... 11 2 Drug licensing and pharmacovigilance .......................................................